← All diseases
Muscles and connective tissue
Severe myasthenia gravis
Would you like to receive a message when there is new research on Severe myasthenia gravis? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, above each publication you'll see one sentence explaining what was researched — and you'll be notified as soon as there is new research on Severe myasthenia gravis. View what Premium costs.
Publications and studies (1467)
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Qiangji Jianli Decoction attenuates skeletal muscle injury in rats with experimental autoimmune myasthenia gravis via the GRP78/IRE1α/GPX4 signaling pathway. (2026/05/10) ♡
- Formative Research in the Codesign of a Discrete Choice Experiment with Patients with Myasthenia Gravis: Selecting and Refining Attributes, Levels and Scenarios. (2026/05/01) ♡
- In-Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis. (2026/05/01) ♡
- Prevalence and predictors of low bone mineral density in Myasthenia gravis. (2026/05/01) ♡
- Organ-specific autoimmunity in primary Sjögren's disease. (2026/05/01) ♡
- Docosahexaenoic acid supplementation aggravates myasthenia gravis through immune dysregulation. (2026/05/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Impact of a ketogenic diet on clinical outcomes and immunological markers in myasthenia gravis: A randomized pilot study. (2026/05/01) ♡
- High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies. (2026/04/02) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Pseudoptosis due to acute dacryoadenitis: An unusual presentation of Epstein-Barr virus infection in a child. (2026/04/01) ♡
- SEC-based isolation of phosphatidylserine-liposomes from biological samples for preclinical studies. (2026/03/16) ♡
- Muscle expression of PD1 and PD-L1 may predict the severity and outcomes of neuromuscular immune-related adverse events caused by immune checkpoint inhibitor treatment. (2026/03/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. The Case of a 28-Year-Old Man With Gradually Progressive Proximal Leg Weakness. (2026/03/01) ♡
- [Adherence to the Mediterranean diet and anthropometric characteristics in patients with myasthenia gravis: a retrospective cohort study]. (2026/03/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Pharmacological and speech-language pathology management of dysphagia in patients with myasthenia gravis. (2026/03/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Prevalence and trajectories of post-COVID-19 neuromuscular conditions: A systematic-review and meta-analysis. (2026/02/15) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. ST-Segment Elevation Myocardial Infarction in a Patient With Myasthenia Gravis After Intravenous Immunoglobulin Infusion. (2026/02/11) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Global Research Landscape in T Cells and Myasthenia Gravis: Trends, Collaborations, and Future Directions. (2026/02/05) ♡
- Prognosis After Discontinuation of Azathioprine or Mycophenolate Mofetil in Well-Controlled Myasthenia Gravis: A Retrospective Analysis. (2026/02/01) ♡
- Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA. (2026/02/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Humoral correlates of clinical response to thymectomy in myasthenia gravis. (2026/02/01) ♡
- Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis. (2026/02/01) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Sleep disorders in myasthenia gravis: A systematic review on prevalence, clinical associations, and the accuracy of assessment methodologies. (2026/02/01) ♡
- The Disparities in Myasthenia Gravis Clinical Trial Enrollment in the United States and Canada. (2026/02/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Challenges in myasthenia gravis diagnosis: an analysis of the diagnostic process of myasthenia gravis in a specialized clinic. (2026/02/01) ♡
- Telitacicept demonstrates high probability of efficacy in myasthenia gravis: a Bayesian real-world study. (2026/01/27) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Serological testing patterns among individuals newly diagnosed with myasthenia gravis. (2026/01/15) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Ipilimumab/nivolumab-induced severe triple M syndrome in a patient with metastatic renal cancer. (2026/01/15) ♡
- ENGAGE: Analyzing the value of virtual reality in a patient-centric immersive learning program in myasthenia gravis for healthcare professionals. (2026/01/13) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. The rare report of unicentric Castleman disease with concurrent myasthenia gravis and paraneoplastic pemphigus: a case report with a focused review of the literature. (2026/01/12) ♡
- Exploring the impact of age of onset on stereoacuity in patients with myasthenia gravis. (2026/01/12) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Antibody-Microbiota Interface in Autoimmune Diseases. (2026/01/10) ♡
- Add-on efgartigimod in myasthenic crisis: a promising treatment option. (2026/01/08) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single case report. (2026/01/07) ♡
- Treatment guidelineiAn official agreement between doctors about how this disease should be treated. This is not a single study but the conclusion of an entire medical field. Portuguese Consensus Guidelines for the Diagnosis and Treatment of Myasthenia Gravis. (2026/01/02) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: Immune checkpoint inhibitor-associated myocarditis in an esophageal cancer patient with myasthenia gravis following combined radiotherapy and immunotherapy. (2026/01/02) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The telemedical platform MyaLink for remote monitoring in myasthenia gravis - rationale and protocol for a proof of concept study. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Neuro-ophthalmic Manifestations of Multiple Sclerosis. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Myasthenia Gravis - An Updated Review. (2026/01/01) ♡
- Plasma miR-150-5p as a biomarker for immunosuppressive therapy response in acetylcholine receptor positive myasthenia gravis: a long-term prospective longitudinal study. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Association of Individual or Family History of Autoimmune Disease With Future Development of Type 1 Diabetes. (2026/01/01) ♡
- Cytokine Changes With Effective Drug Therapy for Juvenile Myasthenia Gravis. (2026/01/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA) (2026-08-11) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis (2026-08-10) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. MuSK Myasthenia 1000 Study (2026-08-05) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC) (2026-08-04) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) (2026-08-03) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis (2026-08-03) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Study of Aritinercept in Patients With Generalized Myasthenia Gravis (2026-08-03) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis (2026-07-31) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis (2026-07-31) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.